Since XPO1 inhibition potently downregulate HOX expression in NPM1-mutated AML, the combination of menin and XPO1 inhibitors appeals as a rational therapeutic option in NPM1-mutated AML (48). The gene discussed is NPM1; the disease is acute myeloid leukemia.